Patents by Inventor Stefan Roos
Stefan Roos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082325Abstract: A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.Type: ApplicationFiled: November 16, 2023Publication date: March 14, 2024Applicant: BioGaia ABInventors: Stefan Roos, Wolfgang Kunze, John Bienenstock
-
Patent number: 11911424Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.Type: GrantFiled: July 24, 2019Date of Patent: February 27, 2024Assignee: BioGaia ABInventors: Stefan Roos, Bo Möllstam
-
Patent number: 11857582Abstract: A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.Type: GrantFiled: April 17, 2020Date of Patent: January 2, 2024Assignee: BioGaia ABInventors: Stefan Roos, Wolfgang Kunze, John Bienenstock
-
Publication number: 20230405062Abstract: The invention herein relates generally to enhancing the survival and activity of probiotic Lactobacillus reuteri strains in mammals by pre-conditioning L. reuteri with GOS during cultivation and to a surprisingly high symbiotic effect of such a pre-conditioned probiotic L. reuteri strain when administered together with GOS further added in the composition. The invention therefore comprises methods for cultivating and manufacturing probiotic L. reuteri strains, and preparing products containing such pre-conditioned strains in combination with additional amounts of GOS. In more detail the present invention relates to a probiotic composition comprising a probiotic L. reuteri strain, obtained by a step of growing the bacteria in a medium comprising GOS, and administering the pre-conditioned bacteria together with further GOS in the final product. The inventors have found that such method induces surprisingly high and unexpected symbiotic beneficial effects of the probiotic bacteria in the gastrointestinal tract.Type: ApplicationFiled: March 11, 2022Publication date: December 21, 2023Inventors: Stefan ROOS, Marie Noëlle HORCAJADA, Nicolas BONNET, Magalie SABATIER, Bertrand BOURQUI, Guénolée Eliane Marie PRIOULT, Florac DE BRUYN
-
Publication number: 20230362468Abstract: An optical sensor system (1) has plural optical lens systems (2a-2n), a single imaging optical sensor (3) and plural light guides (4a-4n) corresponding to the number of optical lens systems (2a-2n). The light guides (4a-4n) extend respectively between the lens systems (2a-2n) and the optical sensor (3). Each of the lens systems (2a-2n) is associated respectively with one of the light guides (4a-4n). A switching apparatus (5) selectively switches between the light guide means (4a-4n).Type: ApplicationFiled: May 4, 2023Publication date: November 9, 2023Inventors: Simon Isele, Stefan Roos, Lukas Ewecker
-
Publication number: 20230338441Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.Type: ApplicationFiled: June 29, 2023Publication date: October 26, 2023Inventor: Stefan Roos
-
Patent number: 11730780Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.Type: GrantFiled: February 14, 2022Date of Patent: August 22, 2023Assignee: BIOGAIA ABInventor: Stefan Roos
-
Publication number: 20230227771Abstract: The present invention relates to a probiotic Lactobacillus reuteri strain obtained by growing the bacteria in a medium comprising galacto-oligosaccharides (GOS), so called pre-conditioning. The pre-conditioning method provides boosting effects of the probiotic L. reuteri strain, such as improved mineral absorption, in the gastrointestinal tract. The invention comprises methods for manufacturing and cultivating probiotic Lactobacillus reuteri strains, and products and first and second medical uses of such strains.Type: ApplicationFiled: March 11, 2022Publication date: July 20, 2023Inventors: Stefan ROOS, Marie Noëlle HORCAJADA, Nicolas BONNET, Magalie SABATIER, Bertrand BOURQUI, Guénolée Eliane Marie PRIOULT, Florac DE BRUYN
-
Patent number: 11602551Abstract: The present invention provides the use of inosine in the treatment of a disease associated with Treg deficiency or Treg dysfunction, in particular immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). In one embodiment of the invention, the inosine can be provided in the form of a bacterial strain that is capable of stimulating the production of inosine. Methods for stimulating the production of inosine in a subject using said strains are also provided, as are methods for the selection of a bacterial strain capable of stimulating inosine production in a subject.Type: GrantFiled: May 26, 2017Date of Patent: March 14, 2023Assignees: BioGaia AB, Board of Regents of the University of Texas SystemInventors: Stefan Roos, Yuying Liu, Baokun He, Jon Marc Rhoads
-
Publication number: 20230057324Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of adenosine, for use in the production of adenosine in a subject. Therapeutic uses of such strains include the treatment or prevention of diseases associated with adenosine deficiency, for example wound healing. Novel strains are also provided.Type: ApplicationFiled: July 24, 2019Publication date: February 23, 2023Applicant: BioGaia ABInventor: Stefan Roos
-
Publication number: 20220354909Abstract: The invention relates to selection of bacterial strain for use in treating serotonin deficiency and/or a disease related to serotonin deficiency by culturing bacteria of a lactic acid producing bacterial strain, under aerobic conditions, in a culture medium comprising tryptophan. Any serotonin produced by the bacteria of the lactic acid producing bacterial strain in the culture medium is detected and the lactic acid producing bacterial strain is selected as effective in treating serotonin deficiency and/or a disease related to serotonin deficiency in a subject if serotonin is detected in the culture medium.Type: ApplicationFiled: November 6, 2020Publication date: November 10, 2022Inventors: Estelle Grasset, Muhammed Khan, Bo Möllstam, Stefan Roos
-
Publication number: 20220347237Abstract: The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.Type: ApplicationFiled: July 24, 2019Publication date: November 3, 2022Applicant: BioGaia ABInventors: Stefan Roos, Bo Möllstam
-
Publication number: 20220168365Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.Type: ApplicationFiled: February 14, 2022Publication date: June 2, 2022Inventor: Stefan Roos
-
Patent number: 11285181Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.Type: GrantFiled: March 27, 2018Date of Patent: March 29, 2022Assignee: Biogaia ABInventor: Stefan Roos
-
Publication number: 20210154245Abstract: A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.Type: ApplicationFiled: April 17, 2020Publication date: May 27, 2021Applicant: BioGaia ABInventors: Stefan Roos, Wolfgang Kunze, John Bienenstock
-
Publication number: 20210060098Abstract: The present invention provides the use of inosine in the treatment of a disease associated with Treg deficiency or Treg dysfunction, in particular immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). In one embodiment of the invention, the inosine can be provided in the form of a bacterial strain that is capable of stimulating the production of inosine. Methods for stimulating the production of inosine in a subject using said strains are also provided, as are methods for the selection of a bacterial strain capable of stimulating inosine production in a subject.Type: ApplicationFiled: May 26, 2017Publication date: March 4, 2021Applicants: BioGaia AB, Board of Regents of the University of Texas SystemInventors: Stefan Roos, Yuying Liu, Baokun He, Jon Marc Rhoads
-
Publication number: 20200038461Abstract: The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.Type: ApplicationFiled: March 27, 2018Publication date: February 6, 2020Inventor: Stefan ROOS
-
Publication number: 20170304376Abstract: The present invention relates to methods of activating live lactic acid bacteria comprising exposing said bacteria to a preparation comprising citrate, wherein said bacteria have the ability to utilize citrate as an external electron acceptor. The present invention further relates to methods to enhance the activity of certain live bacteria in mammals. More specifically the invention relates to improve the wake-up of certain lactic acid bacteria from the freeze-dried state. The present invention also relates to preparations comprising said activated bacteria and therapeutic uses of said activated bacteria.Type: ApplicationFiled: January 14, 2016Publication date: October 26, 2017Inventors: Staffan Strömberg, Eamonn Connolly, Stefan Roos
-
Publication number: 20150104852Abstract: Methods for the control led activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.Type: ApplicationFiled: December 19, 2014Publication date: April 16, 2015Inventor: Stefan Roos
-
Patent number: 8945534Abstract: Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.Type: GrantFiled: November 4, 2013Date of Patent: February 3, 2015Assignee: BioGaia ABInventor: Stefan Roos